Back to search

Peptide record

TPDB09865

Maculatin 1.3 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09865
Maculatin 1.3
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab Antifungipept AI4AVP dbAMP 3.0 DRAVP 2.0 APD_complete PD_Hemolysis ToxinPred 3.0
standard
No
A 21-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GLLGLLGSVVSHVVPAIVGHF
Physicochemical Analysis
C98H159N25O24
RNDCEQKMTWY
V
2071.49
8.00
2
0
12
+0
-0.83
1.624
166.67
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
2
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
4
G
2
H
1
I
4
L
0
K
0
M
1
F
1
P
2
S
0
T
0
W
0
Y
5
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 4 H: 2 I: 1 L: 4 K: 0 M: 0 F: 1 P: 1 S: 2 T: 0 W: 0 Y: 0 V: 5
Chemical Descriptors
21
C98H159N25O24
2071.49
8.00
+0
-0.83
1.624
Free
L
Not Available
Free
Anticancer
Blue-thighed frog,Litoria chloris, Australia
Evidence Records 20 records
Evidence 1 Activity

Activity

MIC
Antibacterial
6.2 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
active against S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek
Evidence 2 Activity

Activity

MIC
Antibacterial
>100 µM

Target

E.coli

Source & Reference

dbAMP DRAMP

Other

active against S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek et al., 2012 ). inhib
Evidence 3 Activity

Activity

MIC
Antibacterial
25 µM

Target

B. subtilis

Source & Reference

dbAMP DRAMP

Other

active against S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek et al., 2012 ). inhibited Human Immunodeficien
Evidence 4 Activity

Activity

MIC
Antibacterial
>100 µM

Target

P.aeruginosa

Source & Reference

dbAMP DRAMP

Other

st S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek et al., 2012 ). inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 4.0
Evidence 5 Activity

Activity

Not Available
Anticancer

Target

Skin Cancer
Not Available
Not Available

Assay & Model

Not Available
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 6 Activity

Activity

MIC
Antifungal
6.2 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

dbAMP DRAMP Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
active against S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek
Evidence 7 Activity

Activity

MIC
Antifungal
>100 µM

Target

E.coli

Source & Reference

dbAMP DRAMP Antifungipept

Other

active against S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek et al., 2012 ). inhib
Evidence 8 Activity

Activity

MIC
Antifungal
25 µM

Target

B. subtilis

Source & Reference

dbAMP DRAMP Antifungipept

Other

active against S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek et al., 2012 ). inhibited Human Immunodeficien
Evidence 9 Activity

Activity

MIC
Antifungal
>100 µM

Target

P.aeruginosa

Source & Reference

dbAMP DRAMP Antifungipept

Other

st S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek et al., 2012 ). inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 4.0
Evidence 10 Activity

Activity

MIC
Antiparasitic
6.2 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
active against S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek
Evidence 11 Activity

Activity

MIC
Antiparasitic
>100 µM

Target

E.coli

Source & Reference

dbAMP 3.0 DRAMP

Other

active against S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek et al., 2012 ). inhib
Evidence 12 Activity

Activity

MIC
Antiparasitic
25 µM

Target

B. subtilis

Source & Reference

dbAMP 3.0 DRAMP

Other

active against S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek et al., 2012 ). inhibited Human Immunodeficien
Evidence 13 Activity

Activity

MIC
Antiparasitic
>100 µM

Target

P.aeruginosa

Source & Reference

dbAMP 3.0 DRAMP

Other

st S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek et al., 2012 ). inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 4.0
Evidence 14 Activity

Activity

MIC
Antiviral
6.2 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
active against S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek
Evidence 15 Activity

Activity

MIC
Antiviral
>100 µM

Target

E.coli

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

active against S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek et al., 2012 ). inhib
Evidence 16 Activity

Activity

MIC
Antiviral
25 µM

Target

B. subtilis

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

active against S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek et al., 2012 ). inhibited Human Immunodeficien
Evidence 17 Activity

Activity

MIC
Antiviral
>100 µM

Target

P.aeruginosa

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

st S. aureus USA300 MRSA (MIC 6.2 uM), E.coli (MIC >100 uM), B. subtilis (MIC 25 uM), and P.aeruginosa (MIC >100 uM) ( Menousek et al., 2012 ). inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 4.0
Evidence 18 Activity

Activity

50% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
50% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Database screening and in vivo efficacy of antimicrobial peptides against methicillin-resistant Staphylococcus aureus USA300. | Int J Antimicrob Agents | 2012
Evidence 19 Activity

Activity

50% Cell death
Toxicity
8.02 µM
Cytotoxic
50% Cell death | 8.02 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. | Antimicrob Agents Chemother | 2010
Evidence 20 Hemolysis

Source & Reference

APD_complete PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.